These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38087705)

  • 1. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Baker S; Arbour G; Stefanyk K; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):148-156. PubMed ID: 38087705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
    Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study.
    Choi SH; Lee BM; Kim J; Kim DY; Seong J
    J Hepatol; 2024 Jul; 81(1):84-92. PubMed ID: 38467379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
    Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
    BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
    JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
    Olson R; Senan S; Harrow S; Gaede S; Louie A; Haasbeek C; Mulroy L; Lock M; Rodrigues G; Yaremko B; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman G; Warner A; Palma D
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):943-947. PubMed ID: 31470091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
    Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis.
    Helou J; Thibault I; Chu W; Munoz-Schuffenegger P; Erler D; Rodrigues G; Warner A; Chan KKW; Chow E; Korol R; Davidson M; Chung HT
    Radiother Oncol; 2018 Dec; 129(3):435-440. PubMed ID: 30274721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
    Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
    Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
    Olson R; Liu M; Bergman A; Lam S; Hsu F; Mou B; Berrang T; Mestrovic A; Chng N; Hyde D; Matthews Q; Lund C; Glick D; Pai H; Basran P; Carolan H; Valev B; Lefresene S; Tyldesley S; Schellenberg D
    BMC Cancer; 2018 Oct; 18(1):954. PubMed ID: 30286739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
    Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
    Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
    Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
    JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
    Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
    Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
    Harrow S; Palma DA; Olson R; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Senthi S; Swaminath A; Kopek N; Liu M; Schlijper R; Bauman GS; Laba J; Qu XM; Warner A; Senan S
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):611-616. PubMed ID: 35643253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
    Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
    Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
    Mercier C; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Debois H; Huget P; Verellen D
    Radiat Oncol; 2018 Aug; 13(1):152. PubMed ID: 30126440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.